Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Debt (2020)

Vistagen Therapeutics (VTGN) has disclosed Non-Current Debt for 2 consecutive years, with $87300.0 as the latest value for Q3 2020.

  • Quarterly Non-Current Debt changed N/A to $87300.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $87300.0 through Sep 2020, changed N/A year-over-year, with the annual reading at $27200.0 for FY2016, N/A changed from the prior year.
  • Non-Current Debt hit $87300.0 in Q3 2020 for Vistagen Therapeutics, down from $124700.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $124700.0 in Q2 2020 to a low of $27200.0 in Q1 2016.